Skip to main content

Advertisement

Articles

Page 3 of 35

  1. Hyperglycemia has detrimental effect on ischemic myocardium, but the impact of acute hyperglycemia on the myocardium in asymptomatic diabetic patients has not been fully elucidated. Thus, this follow-up study ...

    Authors: Jelena Bogdanović, Milika Ašanin, Gordana Krljanac, Nebojša M. Lalić, Aleksandra Jotić, Sanja Stanković, Nataša Rajković, Ljubica Stošić, Iva Rasulić, Jelena Milin, Dragana Popović, Ljiljana Bogdanović and Katarina Lalić

    Citation: Cardiovascular Diabetology 2019 18:68

    Content type: Original investigation

    Published on:

  2. Pioglitazone is an oral antidiabetic drug with multiple pleiotropic actions. Recent clinical trials have demonstrated that treatment with pioglitazone reduces cardiovascular risk in patients who have had an is...

    Authors: Min-Hee Woo, Hye Sun Lee and Jinkwon Kim

    Citation: Cardiovascular Diabetology 2019 18:67

    Content type: Original investigation

    Published on:

  3. The mechanisms underlying increased mortality in patients with diabetes and admission hyperglycemia after an acute coronary syndrome may involve reduced capacity for cardioprotection. We investigated the impac...

    Authors: Steen Buus Kristiansen, Kim Bolther Pælestik, Jacob Johnsen, Nichlas Riise Jespersen, Kasper Pryds, Marie Vognstoft Hjortbak, Rebekka Vibjerg Jensen and Hans Erik Bøtker

    Citation: Cardiovascular Diabetology 2019 18:66

    Content type: Original investigation

    Published on:

  4. Haptoglobin (Hp) is an abundant plasma protein with anti-oxidant properties. Hp polymorphism is associated with cardio-metabolic dysfunction but the allele conferring risk of developing acute myocardial infarc...

    Authors: Resham L. Gurung, M. Yiamunaa, Sylvia Liu, Jian Jun Liu, Clara Chan, Robin Wai Munn Choo, Keven Ang, Chee Fang Sum, Subramaniam Tavintharan and Su Chi Lim

    Citation: Cardiovascular Diabetology 2019 18:65

    Content type: Original investigation

    Published on:

  5. Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM). In the...

    Authors: Salvatore Carbone and Dave L. Dixon

    Citation: Cardiovascular Diabetology 2019 18:64

    Content type: Review

    Published on:

  6. Diabetes mellitus (DM) on insulin is a patient-related factor in the assessment of surgical risk based on the EuroSCORE II and, as such, it confers additional risk on outcomes after transcatheter aortic valve ...

    Authors: Panagiotis Tzamalis, Valentin Herzberger, Jens Bergmann, Alexander Wuerth, Peter Bramlage, Holger Schroefel, Claus Schmitt and Gerhard Schymik

    Citation: Cardiovascular Diabetology 2019 18:63

    Content type: Original investigation

    Published on:

  7. Although microvascular dysfunction is known to result from diabetes, it might also lead to diabetes. Lower values of C2, a derivative of the radial artery pressure waveform, indicate microvascular dysfunction ...

    Authors: Daniel A. Duprez, Nkete I. Forbang, Matthew A. Allison, Carmen A. Peralta, Steven Shea and David R. Jacobs Jr.

    Citation: Cardiovascular Diabetology 2019 18:62

    Content type: Original investigation

    Published on:

  8. The relationship between dyslipidemia, inflammation and CV organ damage in type 2 diabetes mellitus (T2DM) is complex. Insulin resistance and inflammatory cytokines interleukins (ILs) increase plasma triglycer...

    Authors: Michaela Kozakova, Carmela Morizzo, Isabel Goncalves, Andrea Natali, Jan Nilsson and Carlo Palombo

    Citation: Cardiovascular Diabetology 2019 18:61

    Content type: Original investigation

    Published on:

  9. The main aims of this study were to examine the incidence and in-hospital outcomes of mechanical and bioprosthetic surgical mitral valve replacement (SMVR) among patients with and without T2DM.

    Authors: Ana López-de-Andrés, Javier de Miguel-Díez, Nuria Muñoz-Rivas, Valentín Hernández-Barrera, Manuel Méndez-Bailón, José M. de Miguel-Yanes and Rodrigo Jiménez-García

    Citation: Cardiovascular Diabetology 2019 18:60

    Content type: Original investigation

    Published on:

  10. The efficacy of ertugliflozin, a sodium–glucose cotransporter 2 inhibitor, for glycemic and blood pressure (BP) control has been demonstrated in phase 3 studies. To further evaluate the effects of ertugliflozi...

    Authors: Jie Liu, Annpey Pong, Silvina Gallo, Amanda Darekar and Steven G. Terra

    Citation: Cardiovascular Diabetology 2019 18:59

    Content type: Original investigation

    Published on:

  11. The aim was to assess coronary atherosclerosis, plaque morphology and associations to cardiovascular risk factors and epicardial adipose tissue (EAT) in patients with long duration of type 1 diabetes mellitus ...

    Authors: Mona Svanteson, Kristine Bech Holte, Ylva Haig, Nils Einar Kløw and Tore Julsrud Berg

    Citation: Cardiovascular Diabetology 2019 18:58

    Content type: Original investigation

    Published on:

  12. Dyslipidaemia has always been regarded as the cornerstone of arteriosclerosis and is related to the pathogenesis of renal insufficiency. However, it is unclear which routinely available lipid parameter is rela...

    Authors: Yu-Xia Wang, An-Ping Wang, Ying-Nan Ye, Zheng-Nan Gao, Xu-Lei Tang, Li Yan, Qin Wan, Wei-Qing Wang, Zuo-Jie Luo, Gui-Jun Qin, Lu-Lu Chen and Yi-Ming Mu

    Citation: Cardiovascular Diabetology 2019 18:57

    Content type: Original investigation

    Published on:

  13. Myocardial energetic efficiency (MEE), is a strong predictor of CV events in hypertensive patient and is reduced in patients with diabetes and metabolic syndrome. We hypothesized that severity of insulin resis...

    Authors: Costantino Mancusi, Giovanni de Simone, Lyle G. Best, Wenyu Wang, Ying Zhang, Mary J. Roman, Elisa T. Lee, Barbara V. Howard and Richard B. Devereux

    Citation: Cardiovascular Diabetology 2019 18:56

    Content type: Original investigation

    Published on:

  14. Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2...

    Authors: Maurice B. Bizino, Ingrid M. Jazet, Jos J. M. Westenberg, Huub J. van Eyk, Elisabeth H. M. Paiman, Jan W. A. Smit and Hildebrandus J. Lamb

    Citation: Cardiovascular Diabetology 2019 18:55

    Content type: Original investigation

    Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2019 18:101

  15. With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) i...

    Authors: Fei Luo, Avash Das, Jingfei Chen, Panyun Wu, Xiangping Li and Zhenfei Fang

    Citation: Cardiovascular Diabetology 2019 18:54

    Content type: Review

    Published on:

  16. Prediabetes is a well-established risk factor for progression to overt diabetes mellitus (DM), which is in turn associated with development of hypertension (HTN) and vice versa. However, the role of prediabete...

    Authors: Mika Geva, Gadi Shlomai, Anat Berkovich, Elad Maor, Avshalom Leibowitz, Alexander Tenenbaum and Ehud Grossman

    Citation: Cardiovascular Diabetology 2019 18:53

    Content type: Original investigation

    Published on:

  17. Despite revascularisation, a large proportion of acute coronary syndrome (ACS) patients continue to experience major adverse cardiovascular events (MACEs), which are worsened by diabetes mellitus (DM). Fibrino...

    Authors: Lisha Zhang, Chenbo Xu, Junhui Liu, Xiaofang Bai, Ruifeng Li, Lijun Wang, Juan Zhou, Yue Wu and Zuyi Yuan

    Citation: Cardiovascular Diabetology 2019 18:52

    Content type: Original investigation

    Published on:

  18. Evidence from imaging studies suggests a high prevalence of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). However, there are no criteria for initiating screening for CAD in th...

    Authors: Shreenidhi M. Venuraju, Avijit Lahiri, Anand Jeevarethinam, Mark Cohen, Daniel Darko, Devaki Nair, Miranda Rosenthal and Roby D. Rakhit

    Citation: Cardiovascular Diabetology 2019 18:51

    Content type: Original investigation

    Published on:

  19. To investigate the effect of visit-to-visit fasting plasma glucose (FPG) variability on the left cardiac structure and function in patients with type 2 diabetes mellitus (T2DM).

    Authors: Xixiang Tang, Junlin Zhong, Hui Zhang, Yanting Luo, Xing Liu, Long Peng, Yanling Zhang, Xiaoxian Qian, Boxiong Jiang, Jinlai Liu, Suhua Li and Yanming Chen

    Citation: Cardiovascular Diabetology 2019 18:50

    Content type: Original investigation

    Published on:

  20. Type 2 diabetes mellitus (T2DM) is associated with a hypercoagulable state and increased neutrophil extracellular traps formation (NETosis). We investigated predictors of NETosis and cell death markers in circ...

    Authors: Agata H. Bryk, Shannon M. Prior, Krzysztof Plens, Malgorzata Konieczynska, Jerzy Hohendorff, Maciej T. Malecki, Saulius Butenas and Anetta Undas

    Citation: Cardiovascular Diabetology 2019 18:49

    Content type: Original investigation

    Published on:

  21. The importance of triglycerides (TG) level as a risk factor for cardiovascular diseases (CVD) has been extensively investigated in the general population; however, their relationship in patients with type 2 di...

    Authors: Xiaofeng Ye, Wen Kong, Mohammad Ishraq Zafar and Lu-Lu Chen

    Citation: Cardiovascular Diabetology 2019 18:48

    Content type: Review

    Published on:

  22. The cardiovascular (CV) safety in terms of heart failure among different classes of treatment remains largely unknown. We sought to assess the comparative effect of these agents on heart failure outcomes.

    Authors: Da-ya Yang, Xin He, Hui-wei Liang, Shao-zhao Zhang, Xiang-bin Zhong, Chu-fan Luo, Zhi-min Du, Jian-gui He, Xiao-dong Zhuang and Xin-xue Liao

    Citation: Cardiovascular Diabetology 2019 18:47

    Content type: Review

    Published on:

  23. SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight. However, it is unclear which body compartments are reduced and to what extent.

    Authors: Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche and Ferruh Artunc

    Citation: Cardiovascular Diabetology 2019 18:46

    Content type: Original investigation

    Published on:

  24. Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and ...

    Authors: Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen and An-Sheng Lee

    Citation: Cardiovascular Diabetology 2019 18:45

    Content type: Original investigation

    Published on:

  25. Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.

    Authors: Agnes Bosch, Christian Ott, Susanne Jung, Kristina Striepe, Marina V. Karg, Dennis Kannenkeril, Thomas Dienemann and Roland E. Schmieder

    Citation: Cardiovascular Diabetology 2019 18:44

    Content type: Original investigation

    Published on:

  26. Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in...

    Authors: Evgenia Gourgari, Junfeng Ma, Martin P. Playford, Nehal N. Mehta, Radoslav Goldman, Alan T. Remaley and Scott M. Gordon

    Citation: Cardiovascular Diabetology 2019 18:43

    Content type: Original investigation

    Published on:

  27. We aimed to compare early and late outcomes after carotid endarterectomy (CEA) between Korean type 2 diabetic and non-diabetic patients and to investigate the impact of diabetes on the overall incidence of car...

    Authors: Min-Jae Jeong, Hyunwook Kwon, Chang Hee Jung, Sun U. Kwon, Min-Ju Kim, Youngjin Han, Tae-Won Kwon and Yong-Pil Cho

    Citation: Cardiovascular Diabetology 2019 18:41

    Content type: Original investigation

    Published on:

  28. Diabetic nephropathy (DN) is characterized by glomerular and tubulointerstitial injury, proteinuria and remodeling. Here we examined whether the combination of an inhibitor of neprilysin (sacubitril), a natriu...

    Authors: Javad Habibi, Annayya R. Aroor, Nitin A. Das, Camila M. Manrique-Acevedo, Megan S. Johnson, Melvin R. Hayden, Ravi Nistala, Charles Wiedmeyer, Bysani Chandrasekar and Vincent G. DeMarco

    Citation: Cardiovascular Diabetology 2019 18:40

    Content type: Original investigation

    Published on:

  29. The efficacy of cell transplantation in heart failure is reportedly modest, but adjuvant drugs combined with cell therapy may improve this efficacy. Peroxisome proliferator-activated receptor (PPAR)γ, one of t...

    Authors: Daisuke Mori, Shigeru Miyagawa, Ryohei Matsuura, Nagako Sougawa, Satsuki Fukushima, Takayoshi Ueno, Koichi Toda, Toru Kuratani, Koichi Tomita, Norikazu Maeda, Iichiro Shimomura and Yoshiki Sawa

    Citation: Cardiovascular Diabetology 2019 18:39

    Content type: Original investigation

    Published on:

  30. Using a meta-analysis of randomized controlled trials (RCTs), this study aimed to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, i...

    Authors: Satoshi Ida, Ryutaro Kaneko and Kazuya Murata

    Citation: Cardiovascular Diabetology 2019 18:38

    Content type: Original investigation

    Published on:

  31. Subtle impairments in left ventricular (LV) function and geometry are common findings in individuals with diabetes. However, whether these impairments precede the development of diabetes mellitus (DM) is not e...

    Authors: Daniel Modin, Rasmus Møgelvang, Peter Godsk Jørgensen, Magnus Thorsten Jensen, Jelena P. Seferovic and Tor Biering-Sørensen

    Citation: Cardiovascular Diabetology 2019 18:37

    Content type: Original investigation

    Published on:

  32. Because weight control is a cornerstone of diabetes management, it is important to understand the relationship of weight change to risk of cardiovascular disease (CVD) among patients with type 2 diabetes melli...

    Authors: Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam and Hyuk-Sang Kwon

    Citation: Cardiovascular Diabetology 2019 18:36

    Content type: Original investigation

    Published on:

  33. This pathophysiological study addressed the hypothesis that soluble epoxide hydrolase (sEH), which metabolizes the vasodilator and anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic ...

    Authors: Thomas Duflot, Lucile Moreau-Grangé, Clothilde Roche, Michèle Iacob, Julien Wils, Isabelle Rémy-Jouet, Anne-Françoise Cailleux, Matthieu Leuillier, Sylvanie Renet, Dongyang Li, Christophe Morisseau, Fabien Lamoureux, Vincent Richard, Gaëtan Prévost, Robinson Joannidès and Jérémy Bellien

    Citation: Cardiovascular Diabetology 2019 18:35

    Content type: Original investigation

    Published on:

  34. Exercise, when performed on a regular basis, is a well-accepted strategy to improve vascular function in patients with type 2 diabetes. However, the exercise intensity that yields maximal adaptations on struct...

    Authors: João P. Magalhães, Xavier Melo, Inês R. Correia, Rogério T. Ribeiro, João Raposo, Hélder Dores, Manuel Bicho and Luís B. Sardinha

    Citation: Cardiovascular Diabetology 2019 18:34

    Content type: Original investigation

    Published on:

  35. To evaluate the characteristics of type 2 diabetes (T2DM) patients with or without chronic kidney disease (CKD) in Germany.

    Authors: Peter Bramlage, Stefanie Lanzinger, Gesine van Mark, Eva Hess, Simon Fahrner, Christoph H. J. Heyer, Mathias Friebe, Jochen Seufert, Thomas Danne and Reinhard W. Holl

    Citation: Cardiovascular Diabetology 2019 18:33

    Content type: Original investigation

    Published on:

  36. The authors have retracted this article [1] because they have identified serious errors in their data analysis which change the conclusions of their study. All authors agree with this retraction.

    Authors: Kyoung Min Kim, Kyong Yeun Jung, Han Mi Yun, Seo Young Lee, Tae Jung Oh, Hak Chul Jang and Soo Lim

    Citation: Cardiovascular Diabetology 2019 18:32

    Content type: Retraction Note

    Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:146

  37. Diabetes mellitus (DM) adversely affects morbidity and mortality for major atherosclerosis-related cardiovascular diseases and is associated with increased risk for the development of aortic stenosis. Clinical...

    Authors: Eilon Ram, Alexander Kogan, Shany Levin, Enrique Z. Fisman, Alexander Tenenbaum, Ehud Raanani and Leonid Sternik

    Citation: Cardiovascular Diabetology 2019 18:31

    Content type: Original investigation

    Published on:

  38. The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25–26 October 2018. As in previous years, this summit served as a refe...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Baruch Itzhak, Nebojsa Lalic, Dario Rahelic, Jan Skrha, Paul Valensi and Antonio Ceriello

    Citation: Cardiovascular Diabetology 2019 18:30

    Content type: Commentary

    Published on:

  39. Cardiovascular autonomic neuropathy (CAN) is a major cause of morbidity and mortality in diabetes patients. Although several risk factors for CAN progression have been established, whether CAN is reversible re...

    Authors: Ji Eun Jun, Seung-Eun Lee, Min Sun Choi, Sung Woon Park, You-Cheol Hwang and Jae Hyeon Kim

    Citation: Cardiovascular Diabetology 2019 18:29

    Content type: Original investigation

    Published on:

  40. To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2...

    Authors: Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim and Nam Hoon Kim

    Citation: Cardiovascular Diabetology 2019 18:28

    Content type: Original investigation

    Published on:

  41. Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was th...

    Authors: Guillaume Besch, Sebastien Pili-Floury, Caroline Morel, Martine Gilard, Guillaume Flicoteaux, Lucie Salomon du Mont, Andrea Perrotti, Nicolas Meneveau, Sidney Chocron, Francois Schiele, Herve Le Breton, Emmanuel Samain and Romain Chopard

    Citation: Cardiovascular Diabetology 2019 18:27

    Content type: Original investigation

    Published on:

  42. The prevalence of asymptomatic coronary artery disease (CAD) in type 2 diabetes (T2D) is unclear. We investigated the extent and prevalence of asymptomatic CAD in T2D patients by utilizing invasive coronary an...

    Authors: Satish Arora, Anne Pernille Ofstad, Geir R. Ulimoen, Kåre I. Birkeland, Knut Endresen, Lars Gullestad and Odd Erik Johansen

    Citation: Cardiovascular Diabetology 2019 18:26

    Content type: Original investigation

    Published on:

  43. Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) remains challenging even with modern drug-eluting stents (DES) due to high rates of repeat revascularization. Everolimus-eluting...

    Authors: T. M. Hommels, R. S. Hermanides, S. Rasoul, B. Berta, A. J. J. IJsselmuiden, G. A. J. Jessurun, E. Benit, B. Pereira, G. De Luca and E. Kedhi

    Citation: Cardiovascular Diabetology 2019 18:25

    Content type: Original investigation

    Published on:

  44. In patients with Normal Glucose Tolerance (NGT) some causes of ischemic heart disease (IHD) were not completely investigated. The role both of metabolic milieu and adipokines in IHD progression was not fully inve...

    Authors: Ferdinando Carlo Sasso, Pia Clara Pafundi, Raffaele Marfella, Paolo Calabrò, Federico Piscione, Fulvio Furbatto, Giovanni Esposito, Raffaele Galiero, Felice Gragnano, Luca Rinaldi, Teresa Salvatore, Michele D’Amico, Luigi Elio Adinolfi and Celestino Sardu

    Citation: Cardiovascular Diabetology 2019 18:24

    Content type: Original investigation

    Published on:

  45. Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 bas...

    Authors: Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho and José Francisco Kerr Saraiva

    Citation: Cardiovascular Diabetology 2019 18:23

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2018 17:157

  46. Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes. The timing, relative to disease onset, and degree of glycemic control that r...

    Authors: Jaskanwal D. Sara, Riad Taher, Nikhil Kolluri, Adrian Vella, Lilach O. Lerman and Amir Lerman

    Citation: Cardiovascular Diabetology 2019 18:22

    Content type: Original investigation

    Published on:

  47. There is a mutual interaction between inflammation and endocrine disorders in the development of coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is associated with CAD, and the effects...

    Authors: Huan Liu, Yongnan Lyu, Di Li, Yan Cui, Yun Huang, Wen Dai and Yan Li

    Citation: Cardiovascular Diabetology 2019 18:21

    Content type: Original investigation

    Published on:

  48. Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 ...

    Authors: Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi and Andrea Giaccari

    Citation: Cardiovascular Diabetology 2019 18:20

    Content type: Review

    Published on:

Annual Journal Metrics

Advertisement